Please assess the completion status of the following clinical trial:

Trial Title: Anakinra to Prevent Post-infarction Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Acute (\<24 hours) onset of chest pain~* New or presumably new ST elevation on ECG~* Planned coronary angiography for percutaneous revascularization~Exclusion Criteria:~* Inability to give informed consent~* Late presentation (\>24 hours)~* Unsuccessful revascularization or urgent coronary bypass surgery~* Hemodynamic instability~* End-stage congestive heart failure (AHA/ACC stage C/D, NYHA class IV)~* Preexisting severe LV dysfunction (LVEF\<20%) or severe valvular disease~* Severe asthma~* Pregnancy ( pre-enrollment pregnancy test)~* Contraindications to cardiac MRI or cardiac angiography~* Severe coagulopathy (INR\>2.0, Platelet count\<50,000/mm3)~* Severe renal insufficiency (creatinine clearance \<30 ml/min/m2)~* Recent (\<14 days) use of anti-inflammatory drugs (NSAIDS excluded)~* Chronic inflammatory disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Anakinra 100 mg given daily by subcutaneous injection for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): 0.67 ml of NaCl 0.9% solution

Based on this trial design, predict the completion outcome and termination type (if applicable).